Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Methotrexate in GPA Maintenance
NCT04944524Phase 4Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tofacitinib in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Relapse rate (major or minor) at 12 months. Status: unknown.
02
Drugs
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT04944524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944524.